1. Home
  2. AIRS vs CRDL Comparison

AIRS vs CRDL Comparison

Compare AIRS & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIRS

AirSculpt Technologies Inc.

HOLD

Current Price

$1.93

Market Cap

114.6M

Sector

Health Care

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.02

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRS
CRDL
Founded
2012
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.6M
97.3M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
AIRS
CRDL
Price
$1.93
$1.02
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$2.50
$9.00
AVG Volume (30 Days)
631.1K
317.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$180,350,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.51
$0.77
52 Week High
$12.00
$1.59

Technical Indicators

Market Signals
Indicator
AIRS
CRDL
Relative Strength Index (RSI) 46.54 49.03
Support Level $1.85 $0.96
Resistance Level $3.29 $1.10
Average True Range (ATR) 0.22 0.04
MACD 0.06 0.00
Stochastic Oscillator 52.53 36.19

Price Performance

Historical Comparison
AIRS
CRDL

About AIRS AirSculpt Technologies Inc.

AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: